Well Told Grants

Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT9425-23-KCRP-IDA: DoD Kidney Cancer, Idea Development Award

Closed Closed October 6, 2023 Opportunity HT9425-23-KCRP-IDA

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2023.

Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 11 awards worth $17.3 million in total. Applications closed on October 6, 2023.

From the official notice on Grants.gov, last changed June 5, 2023. Checked November 7, 2026.

Other notices with this title

Defense Health Agency Contracting Activity - DHACA has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
HT942524KCRPIDAJuly 11, 2024Closed October 15, 2024Closed
W81XWH-22-KCRP-IDAApril 11, 2022Closed October 6, 2022Closed
W81XWH-21-KCRP-IDAApril 23, 2021Closed October 5, 2021Closed

Key dates

PostedJune 5, 2023
DeadlineOctober 6, 2023
Archived by Grants.govNovember 5, 2023

Who can apply

This opportunity was open to any type of organization.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

What the grant funds

The FY23 KCRP Idea Development Award is intended to support innovative ideas and high-impact approaches, based on scientifically sound evidence, to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in kidney cancer research. The following are significant features of this award mechanism: Research Approach: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of kidney cancer. Experimental strategies may be novel or may be based on strong rationale derived from previously published data and/or presented preliminary data. The feasibility of the research design and methods should be well-defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Additionally, resources should be identified and availability supported through documentation. Identification of potential problems and pitfalls with alternate approaches should be addressed. A statistical analysis plan for the proposed research should be included, if applicable, as well as a power analysis to support the design and sample size. Preliminary Data: Preliminary data are required but need not be in kidney cancer. Preliminary data may include unpublished or published results from the laboratory of the PI or collaborators named on the application and/or data from the published literature relevant to kidney cancer. Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other creative qualities. This may include high-risk, potentially high-gain, approaches to kidney cancer research, provided the application demonstrates the potential for significant impact on the field of research, patient care, and/or quality of life. Research that is likely to yield only an incremental advance is not considered innovative. Impact: Proposed research projects should address a central critical issue or question in kidney cancer research or clinical care. High-impact research will, if successful, significantly advance current methods and concepts in at least one of the FY23 KCRP Focus Areas.

Category: Science and Technology and other Research and Development.

Who has won Military Medical Research and Development grants before

From fiscal 2021 to 2025, Military Medical Research and Development (12.420) awarded $6.9 billion across 5,470 grant awards, an average of $1.3 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Maryland81$546 million
The Univeristy of Texas M.D. Anderson Cancer CenterTexas139$166 million
The Johns Hopkins UniversityMaryland157$153 million
The Regents of the University of California, San FranciscoCalifornia113$147 million
Duke UniversityNorth Carolina86$123 million

Top states: Maryland ($793 million), California ($751 million), Texas ($598 million), Massachusetts ($586 million), New York ($508 million).

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is HT9425-23-KCRP-IDA still open?

No. It closed on October 6, 2023. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

Who can apply for DoD Kidney Cancer, Idea Development Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

What is the deadline for DoD Kidney Cancer, Idea Development Award?

Closed October 6, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

How much funding is available?

About $17.3 million in total across about 11 awards.

Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.

Similar open grants